Publisher
American Diabetes Association
Subject
Advanced and Specialised Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference4 articles.
1. Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition
2. U.S. Food and Drug Administration . SGLT2 inhibitors: drug safety communication - labels to include warnings about too much acid in the blood and serious urinary tract infections [Internet], 4 December 2015. Available from http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm475553.htm. Accessed 17 November 2016
3. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program
4. Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献